Drug-induced fatty liver disease: An overview of pathogenesis and management
| Autor: | Arun J. Sanyal, Omair Atiq, Vanessa Kuwajima, Sanjaya K. Satapathy, Jeffrey Nadelson |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
medicine.medical_specialty Cirrhosis Drug-Related Side Effects and Adverse Reactions media_common.quotation_subject Specialties of internal medicine Mitochondria Liver Bioinformatics Pathogenesis Insulin resistance Adenosine Triphosphate Non-alcoholic Fatty Liver Disease Predictive Value of Tests Risk Factors Internal medicine Fatty liver medicine Animals Humans Genetic Predisposition to Disease Drug-induced NAFLD media_common Hepatology business.industry Fatty Acids NASH General Medicine medicine.disease Endocrinology Treatment Outcome RC581-951 Liver Perhexiline Steatosis Steatohepatitis business Energy Metabolism Drug-induced NASH medicine.drug |
| Zdroj: | Annals of Hepatology, Vol 14, Iss 6, Pp 789-806 (2015) |
| ISSN: | 1665-2681 |
| Popis: | Over the past decades, many drugs have been identified, that can potentially induce steatohepatitis in the predisposed individual. Classically this has been incriminated to amiodarone, perhexiline, and 4,4'-diethylaminoethoxyhexestrol (DH), all of which have been found to independently induce the histologic picture of non-alcoholic steatohepatitis (NASH). Pathogenetic mechanisms of hepatotoxicity although still evolving, demonstrate that mitochondrial dysfunction, deranged ATP production and fatty acid catabolism likely play an important role. Drugs like steroid hormones can exacerbate the pathogenetic mechanisms that lead to NASH, and other drugs like tamoxifen, cisplatin and irenotecan have been shown to precipitate latent fatty liver as well. Further research aiming to elucidate the pathogenesis of drug-induced steatosis and steatohepatitis is needed in order to better design therapeutic targets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|